A Phase 2 interventional study of IONIS-HBVRx and Placebo in Hepatitis B and Chronic Hepatitis B Atypical, sponsored by GlaxoSmithKline. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-10.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.
Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 13th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 2, and was the 1st registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:
GlaxoSmithKline
Ages 18+
GlaxoSmithKline
Ages 18–65 · Healthy volunteers
National University Health System, Singapore · Sites in Singapore
Ages 21+
By country, each count listing its studies:
bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 2 · Phase 4 1
First in 2017; this study’s year is marked. 1 started in 2017.
This study's enrollment of 31 is below the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 103 across the 16 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
144 studies in Hepatitis B by GlaxoSmithKline: 2 open now, 6 under way, none of them phase 3. Of 136 finished, 69 (51%) have results posted.
Among the 144 studies in Hepatitis B by GlaxoSmithKline, this one is the 130th largest by enrollment of the 137 interventional ones that give a count, is one of 2 that started in 2017, is one of 34 in phase 2, and was the 124th registered.
GlaxoSmithKline’s Hepatitis B studies by the year they started, since 1992.
2 of the studies testing bepirovirsen in Hepatitis B that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905157GlaxoSmithKlineA Study to Compare Blood Levels of Bepirovirsen and Safety Using Different Methods of Injecting in Healthy Adult Participants | 2027-03-30 |
| NCT06497504GlaxoSmithKlineStudy of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus) | 2027-04-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing bepirovirsen in Hepatitis B, from their registry updates:
Among GlaxoSmithKline’s 144 in Hepatitis B:
This tab as a report to print or save as PDF → With an account.
To examine the safety and tolerability of IONIS-HBVRx administration to treatment-naive patients with chronic hepatitis B virus infection
This study examines the effects of IONIS-HBVRx or placebo (3:1 randomization) administered subcutaneously to treatment-naïve patients who are chronically infected with HBV and the effects of subsequent nucleos(t)ide analogue treatment on these patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
History of liver cirrhosis and/or evidence of cirrhosis as determined by any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
Drug: IONIS-HBVRx
Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
Drug: Placebo
Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
Also known as: ISIS 505358
Placebo
Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs >=5%)
An adverse event is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. Any adverse event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any important medical event according to medical judgment were categorized as SAE.
Time frame: Up to Day 211
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK), Gamma-glutamyl Transferase (GGT) and Lactate Dehydrogenase (LDH) Over Time
Blood samples were collected for the analysis of clinical parameters including ALT, ALP, CK, GGT, LDH and AST. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline in Clinical Chemistry Parameters : Albumin and Total Protein Over Time
Blood samples were collected for the analysis of clinical chemistry parameter-albumin and total protein. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline Values in Clinical Chemistry Parameters: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Magnesium, Phosphate, Glucose, Blood Urea Nitrogen, Cholesterol and Urate
Blood samples were collected for the analysis of clinical parameters including sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphate, glucose, blood urea nitrogen (BUN), cholesterol and urate. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Outcome Measure Timeframe: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline Values in Clinical Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Indirect Bilirubin, and Creatinine
Blood samples were collected for the analysis of clinical chemistry parameters: direct bilirubin, total bilirubin, indirect bilirubin and creatinine. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline for Hematology Parameters: Basophils, Eosinophils, White Blood Cells (WBC), Lymphocytes, Neutrophils, Monocytes, and Platelets
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, WBC, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline for Hematology Parameters: Hemoglobin
Blood samples were collected for the analysis of hematology parameters including hemoglobin at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline for Hematology Parameter: Hematocrit
Blood samples were collected for the analysis of hematology parameter including hematocrit at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline Values in Urine Specific Gravity
Urine samples were collected for the analysis of urine specific gravity. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value. Urine specific gravity is measured as the ratio of urine density compared with water density.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio
Urine samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline Values in Urine Protein
Urine samples were collected for the analysis of urine protein. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline Values in Blood Coagulation Factors: Activated Partial Thromboplastin Time and Prothrombin Time
Blood samples were collected for the analysis of blood coagulation factors:activated partial thromboplastin time (aPTT) and Prothrombin Time (PT). Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 23, 57, 85, 211
Change From Baseline Values in Blood Coagulation Factor: Prothrombin International Normalized Ratio
Blood samples were collected for the analysis of blood coagulation factor: Prothrombin International normalized ratio. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 23, 57, 85, 211
Change in Complement C3 Level at Worst Case Post Baseline Relative to Baseline
Blood samples were collected from participants to evaluate change in complement C3 level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement C3 was the minimum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and up to Day 211
Change in Complement C5a Level at Worst Case Post Baseline Relative to Baseline
Blood samples were collected from participants to evaluate change in complement C5a level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement C5a was the maximum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and up to Day 211
Change in Complement Bb Level at Worst Case Post Baseline Relative to Baseline
Blood samples were collected from participants to evaluate change in complement Bb level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement Bb was the maximum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and up to Day 211
Number of Participants With Reported Pregnancy
Female participants who were not surgically sterile or post-menopausal, underwent urine beta Human chorionic gonadotropin (Beta-HCG) pregnancy test.
Time frame: Up to Day 211
Change From Baseline in Body Temperature
Body temperature was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline in Body Weight
Body weight was measured at indicated time points. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 211
Change From Baseline in Diastolic Blood Pressure and Systolic Blood Pressure
Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline in Respiratory Rate
Respiratory Rate was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Change From Baseline in Pulse Rate
Pulse Rate was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Days 29, 57, 85, 211
Number of Participants With Abnormal Findings in Physical Examination
Physical examinations included assessment of the dermatologic, cardiovascular, respiratory, gastrointestinal, and neurological systems.
Time frame: Up to Day 211
Number of Participants Who Received Atleast One Concomitant Medication
A concomitant medication is defined as any medication initiated after the first dose of study, or initiated prior to the first dose of study drug and continued after the first dose of study drug.
Time frame: Up to Day 211
Change From Baseline in Electrocardiogram Mean Ventricular Rate
Triplicate 12-lead Electrocardiograms (ECGs) were recorded at indicated timepoints. At each time point, ECG machine automatically measured mean ventricular rate (VR). Baseline ECG was the average of the triplicate taken on Day 1 Pre-dose, if only 1 or 2 assessments were available, the single assessment or average of the 2 assessments was used. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose); Day1: 3 hours post-dose, 5 hours post-dose; Day 2; Day 22:pre-dose, 3 hours postdose, 5 hours post-dose; Days 23, 29 and 113
Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QT Corrected Interval-Fredericia Interval and QTc Corrected by Bazett's Formula
Triplicate 12-lead Electrocardiograms (ECGs) were recorded at indicated timepoints. At each time point, ECG machine automatically measured QRS duration, uncorrected QT interval, QT corrected interval-Fredericia \[QTcF\] interval and QTc corrected by Bazett's formula (QTcB). Baseline ECG was the average of the triplicate taken on Day 1 Pre-dose, if only 1 or 2 assessments were available, the single assessment or average of the 2 assessments was used. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose); Day1: 3 hours post-dose, 5 hours post-dose; Day 2; Day 22:pre-dose, 3 hours postdose, 5 hours post-dose; Days 23, 29 and 113
Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Day 29
Blood samples were collected from participants to assess HBV DNA viral load. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. The last observation carried forward (LOCF) method was used to impute missing values at Day 29 in this analysis.
Time frame: Baseline (Day 1 pre-dose) and Day 29
Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Week 31
Blood samples were collected from participants to assess HBV DNA viral load. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Week 31
Change From Baseline in HBV Surface Antigen (HBsAg) Level in Serum at Day 29
Blood samples were collected from participants to assess HBsAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. The LOCF method was used to impute missing values at Day 29 in this analysis.
Time frame: Baseline (Day 1 pre-dose) and Day 29
Change From Baseline in HBsAg Level in Serum at Week 31
Blood samples were collected from participants to assess HBsAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1 pre-dose) and Week 31
Percentage of Participants Who Achieved HBsAg Loss at Day 29 and Week 31
Blood samples were collected to evaluate the percentage of participants with HBsAg loss at Day 29 and Week 31. A 'Loss' of HBsAg means antigen is negative. HBsAg Loss percentage is defined as number of participants with HBsAg loss divided by total number of participants assessed multiplied by 100. Baseline is the last non-missing measurement prior to the first dose of study drug.
Time frame: At Day 29 and Week 31
Percentage of Participants Who Achieved HBV e Antigen (HBeAg) Loss at Day 29 and Week 31 Who Were HBeAg Positive at Baseline
Blood samples were collected to evaluate the percentage of participants with HBeAg loss at Day 29 and Week 31. A 'Loss' of HBeAg means antigen is negative. HBeAg Loss percentage is defined as number of participants with HBeAg loss divided by number of participants with positive HBeAg at Baseline multiplied by 100. Baseline is the last non-missing measurement prior to the first dose of study drug. Participants was considered HBeAg positive at Baseline if the Baseline value\> 0.09 U/mL.
Time frame: Baseline (Day 1, Pre dose) and at Day 29 and Week 31
Change From Baseline in Serum HBeAg Concentration at Day 29 in Participants Who Were HBeAg Positive at Baseline
Blood samples were collected from participants to assess HBeAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. Participant was considered HBeAg positive at Baseline if the Baseline value\> 0.09 International Units/milliliter (IU/mL).
Time frame: Baseline (Day 1, Pre dose) and at Day 29
Change From Baseline in Serum HBeAg Concentration at Week 31 in Participants Who Were HBeAg Positive at Baseline
Blood samples were collected from participants to assess HBeAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. Participant was considered HBeAg positive at Baseline if the Baseline value\> 0.09 U/mL.
Time frame: Baseline (Day 1, Pre dose) and Week 31
Plasma Concentrations of GSK3228836 in Participants With Chronic HBV Infection
Plasma samples were collected from participants with chronic HBV infection at indicated time points for pharmacokinetic analysis of GSK3228836.
Time frame: Day 1:pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours post-dose, Days 2 and 23: 24 hours post-dose, Day 4: 72 hours post-dose, Days 8 and 15: pre-dose, Day 22: pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours post-dose, and Days 29, 36, 57, 85, 113, and 211
This study evaluated safety, tolerability, pharmacokinetics and antiviral activity of GSK3228836 in two population of participants with Chronic Hepatitis B (CHB) virus infection: treatment-naive participants (Cohorts 1, 2 and 3) and participants on stable nucleos(t)ide treatment (Cohort 4)
| Milestone | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Started | 6 | 12 | 6 | 5 | 2 |
| Completed | 6 | 12 | 6 | 4 | 2 |
| Not completed | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
An adverse event is any unfavorable and unintended sign (including a clinically-significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE is considered related to the investigational drug product. Any adverse event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect or any important medical event according to medical judgment were categorized as SAE.
| Participants | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Non-SAE (>=5%) | 5 | 6 | 2 | 3 | 0 |
| SAE | 0 | 1 | 0 | 0 | 0 |
Blood samples were collected for the analysis of clinical parameters including ALT, ALP, CK, GGT, LDH and AST. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Units per liter (U/L) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| ALT, Day29, n= 6,12,6,4,2 | 15.7 ± 56.65 | 52.5 ± 112.14 | -0.7 ± 8.91 | 45.3 ± 32.10 | -0.5 ± 3.54 |
| ALT, Day57, n= 5,12,6,4,2 | 45.6 ± 60.06 | 37.5 ± 58.31 | -2.2 ± 8.77 | 46.0 ± 42.31 | 1.0 ± 3.54 |
| ALT, Day85, n= 6,12,6,4,2 | -10.5 ± 30.20 | 8.8 ± 29.87 | 0.5 ± 9.14 | 7.5 ± 13.18 | -0.5 ± 0.71 |
| ALT, Day211, n= 6,12,6,4,2 | -24.3 ± 43.68 | -16.2 ± 30.75 | -3.2 ± 12.88 | 6.5 ± 9.95 | 5.5 ± 3.54 |
| ALP, Day29, n= 6,12,6,4,2 | -3.2 ± 8.23 | 5.2 ± 14.60 | -0.7 ± 8.12 | 9.8 ± 11.95 | 0.0 ± 0.90 |
| ALP, Day57, n= 5,12,6,4,2 | 7.8 ± 12.09 | 13.3 ± 14.55 | 8.0 ± 11.31 | 1.3 ± 9.22 | 4.0 ± 5.66 |
| ALP, Day85, n= 6,12,6,4,2 | 7.2 ± 7.73 | 9.9 ± 9.24 | 7.7 ± 9.89 | 0.0 ± 4.24 | 6.0 ± 4.24 |
| ALP, Day211, n= 6,12,6,4,2 | 18.2 ± 10.32 | 11.3 ± 13.61 | 9.3 ± 8.71 | 1.5 ± 7.85 | 5.0 ± 11.31 |
| AST, Day29, n= 6,12,6,4,2 | 17.7 ± 50.41 | 31.0 ± 78.95 | -0.5 ± 3.99 | 27.5 ± 23.07 | 2.0 ± 1.41 |
| AST, Day57, n= 5,12,6,4,2 | 22.8 ± 34.30 | 23.3 ± 50.25 | 2.3 ± 3.33 | 18.3 ± 15.84 | 4.5 ± 2.12 |
| AST, Day85, n= 6,12,6,4,2 | 3.0 ± 16.66 | 4.6 ± 20.37 | 1.5 ± 4.46 | 5.5 ± 4.51 | 3.0 ± 0.00 |
| AST, Day211, n= 6,12,6,4,2 | -9.3 ± 22.20 | -6.5 ± 16.46 | 3.8 ± 3.76 | 5.3 ± 3.30 | 4.5 ± 2.12 |
| CK, Day29, n= 6,12,6,4,2 | 35.5 ± 127.87 | -17.6 ± 28.46 | -13.2 ± 29.36 | -6.8 ± 19.21 | 49.0 ± 62.23 |
| CK, Day57, n= 5,12,6,4,2 | -9.6 ± 47.77 | 9.8 ± 25.89 | -0.5 ± 24.04 | 57.0 ± 142.54 | 111.0 ± 148.49 |
| CK, Day85, n= 6,12,6,4,2 | 26.2 ± 61.64 | 16.8 ± 28.51 | 5.0 ± 49.78 | 178.8 ± 359.38 | 26.5 ± 31.82 |
| CK, Day211, n= 6,12,6,4,2 | 29.2 ± 71.04 | 24.2 ± 42.39 | 77.2 ± 132.59 | 53.8 ± 50.68 | 94.0 ± 114.55 |
| GGT, Day29, n= 6,12,6,4,2 | -2.3 ± 3.88 | 3.1 ± 8.27 | -11.7 ± 22.27 | 5.3 ± 6.70 | -2.5 ± 2.12 |
| GGT, Day57, n= 5,12,6,4,2 | 1.4 ± 3.44 | 6.5 ± 15.85 | -17.0 ± 36.30 | 9.0 ± 3.74 | 2.0 ± 2.83 |
| GGT, Day85, n= 6,12,6,4,2 | -0.5 ± 1.52 | 3.2 ± 6.66 | -17.5 ± 37.56 | 5.3 ± 3.10 | 1.0 ± 2.83 |
| GGT, Day211, n= 6,12,6,4,2 | -7.7 ± 11.57 | -1.1 ± 2.15 | -17.8 ± 41.06 | 4.3 ± 2.22 | 2.0 ± 1.41 |
| LDH, Day29, n= 6,12,6,4,2 | 12.0 ± 27.03 | 1.7 ± 41.09 | -1.5 ± 15.00 | 46.8 ± 35.51 | 12.5 ± 0.71 |
| LDH, Day57, n= 5,12,6,4,2 | 4.4 ± 26.68 | -4.7 ± 21.40 | 22.0 ± 36.74 | 4.8 ± 9.25 | 11.0 ± 11.31 |
| LDH, Day85, n= 6,12,6,4,2 | 9.5 ± 22.79 | -12.3 ± 22.42 | 29.2 ± 35.29 | 3.8 ± 17.19 | 6.0 ± 8.49 |
| LDH, Day211, n= 6,12,6,4,2 | 7.0 ± 18.78 | 3.3 ± 28.06 | 55.0 ± 54.59 | 25.3 ± 13.60 | 24.0 ± 22.63 |
Blood samples were collected for the analysis of clinical chemistry parameter-albumin and total protein. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Grams per liter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Albumin, Day29, n= 6,12,6,4,2 | -0.8 ± 1.47 | 0.3 ± 2.23 | -1.3 ± 1.51 | 3.0 ± 2.16 | 1.5 ± 3.54 |
| Albumin, Day57, n= 5,12,6,4,2 | 0.6 ± 1.67 | 1.7 ± 2.57 | 0.0 ± 1.55 | 1.8 ± 1.50 | 5.5 ± 0.71 |
| Albumin, Day85, n= 6,12,6,4,2 | 0.0 ± 2.00 | 2.0 ± 3.28 | -0.8 ± 3.19 | 1.3 ± 2.22 | 3.0 ± 2.83 |
| Albumin, Day211, n= 6,12,6,4,2 | 1.0 ± 2.28 | 3.3 ± 2.26 | 0.7 ± 3.01 | 4.3 ± 0.50 | 3.0 ± 5.66 |
| Total Protein, Day29, n= 6,12,6,4,2 | -1.8 ± 2.64 | 1.9 ± 3.18 | -1.8 ± 4.75 | 6.5 ± 3.11 | 1.5 ± 7.78 |
| Total Protein, Day57, n= 5,12,6,4,2 | 0.8 ± 3.49 | 3.8 ± 4.27 | 0.2 ± 3.25 | 3.0 ± 1.41 | 6.0 ± 0.0 |
| Total Protein, Day85, n= 6,12,6,4,2 | 0.8 ± 3.54 | 3.3 ± 5.03 | 0.3 ± 4.97 | 3.5 ± 3.42 | 4.5 ± 2.12 |
| Total Protein, Day211, n= 6,12,6,4,2 | 2.5 ± 4.81 | 5.1 ± 4.23 | 1.7 ± 3.33 | 8.0 ± 2.71 | 4.5 ± 12.02 |
Blood samples were collected for the analysis of clinical parameters including sodium, potassium, chloride, bicarbonate, calcium, magnesium, phosphate, glucose, blood urea nitrogen (BUN), cholesterol and urate. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Millimoles per liter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Bicarbonate, Day29, n= 6,12,6,4,2 | 0.3 ± 1.21 | 0.2 ± 1.11 | 1.0 ± 1.41 | 0.0 ± 2.16 | -2.0 ± 2.83 |
| Bicarbonate, Day57, n= 5,12,6,4,2 | 1.0 ± 2.65 | -0.1 ± 2.02 | -0.2 ± 2.14 | 0.3 ± 2.87 | -3.0 ± 2.83 |
| Bicarbonate, Day85, n= 6,12,6,4,2 | 0.2 ± 3.92 | 0.5 ± 1.83 | -0.8 ± 0.75 | -0.8 ± 0.50 | -2.0 ± 2.83 |
| Bicarbonate, Day211, n= 6,12,6,4,2 | 2.8 ± 1.94 | -1.0 ± 1.81 | -0.8 ± 1.72 | -0.8 ± 2.22 | -2.0 ± 4.24 |
| Calcium, Day29, n= 6,12,6,4,2 | 0.012 ± 0.0811 | 0.015 ± 0.0735 | -0.040 ± 0.0506 | 0.063 ± 0.0479 | -0.030 ± 0.0707 |
| Calcium, Day57, n= 5,12,6,4,2 | 0.036 ± 0.0658 | 0.029 ± 0.0899 | -0.038 ± 0.0471 | 0.013 ± 0.0150 | 0.010 ± 0.0566 |
| Calcium, Day85, n= 6,12,6,4,2 | 0.020 ± 0.0672 | 0.046 ± 0.0944 | -0.028 ± 0.0679 | -0.013 ± 0.0675 | 0.050 ± 0.0707 |
| Calcium, Day211, n= 6,12,6,4,2 | 0.052 ± 0.0618 | 0.056 ± 0.0745 | -0.025 ± 0.0789 | 0.068 ± 0.0746 | -0.025 ± 0.1344 |
| Chloride, Day29, n= 6,12,6,4,2 | -0.8 ± 2.14 | -0.3 ± 1.97 | 0.8 ± 1.94 | -2.0 ± 1.83 | -1.5 ± 0.71 |
| Chloride, Day57, n= 5,12,6,4,2 | -1.2 ± 2.17 | 0.0 ± 1.86 | 0.7 ± 0.82 | -1.0 ± 0.00 | -1.5 ± 0.71 |
| Chloride, Day85, n= 6,12,6,4,2 | -1.0 ± 2.37 | 0.8 ± 1.85 | 1.5 ± 1.64 | -0.3 ± 1.50 | -1.5 ± 2.12 |
| Chloride, Day211, n= 6,12,6,4,2 | -0.8 ± 2.48 | 0.0 ± 2.30 | 1.7 ± 2.94 | -0.5 ± 0.58 | -1.0 ± 1.41 |
| Cholesterol, Day29, n= 6,12,6,4,2 | -0.027 ± 0.2281 | -0.129 ± 0.4305 | -0.252 ± 0.2044 | 0.123 ± 0.9238 | -0.155 ± 0.7000 |
| Cholesterol, Day57, n= 5,12,6,4,2 | -0.422 ± 0.3739 | -0.328 ± 0.8109 | -0.717 ± 0.5216 | 0.480 ± 0.7278 | 0.815 ± 0.5303 |
| Cholesterol, Day85, n= 6,12,6,4,2 | -0.380 ± 0.5772 | -0.211 ± 0.8659 | -0.812 ± 0.2704 | 0.195 ± 0.5073 | 0.390 ± 0.5091 |
| Cholesterol, Day211, n= 6,12,6,4,2 | -0.110 ± 0.4369 | -0.121 ± 0.7581 | -0.423 ± 0.6980 | 0.960 ± 0.3982 | 0.360 ± 0.7354 |
| Glucose, Day29, n= 6,12,6,4,2 | 0.170 ± 0.7148 | 0.009 ± 0.7782 | 0.498 ± 1.3437 | -0.290 ± 0.1299 | 0.225 ± 0.0778 |
| Glucose, Day57, n= 5,12,6,4,2 | 0.056 ± 0.4161 | -0.110 ± 1.0510 | -0.157 ± 0.5147 | 0.415 ± 1.4055 | -0.360 ± 0.1980 |
| Glucose, Day85, n= 6,12,6,4,2 | 0.018 ± 0.3725 | -0.218 ± 1.0970 | -0.315 ± 0.2959 | 0.073 ± 0.4524 | -0.110 ± 0.0000 |
| Glucose, Day211, n= 6,12,6,4,2 | 0.093 ± 0.4956 | -0.205 ± 1.0796 | -0.223 ± 0.5205 | -0.373 ± 0.6375 | -0.110 ± 0.3111 |
| Magnesium, Day29, n= 6,12,6,4,2 | -0.008 ± 0.0376 | 0.013 ± 0.0377 | -0.025 ± 0.0524 | 0.000 ± 0.0000 | 0.025 ± 0.0354 |
| Magnesium, Day57, n= 5,12,6,4,2 | 0.000 ± 0.0500 | 0.038 ± 0.0483 | -0.033 ± 0.0516 | 0.013 ± 0.0479 | 0.000 ± 0.0000 |
| Magnesium, Day85, n= 6,12,6,4,2 | -0.025 ± 0.0612 | 0.029 ± 0.0620 | -0.033 ± 0.0606 | -0.038 ± 0.0479 | 0.000 ± 0.0000 |
| Magnesium, Day211, n= 6,12,6,4,2 | 0.008 ± 0.0585 | 0.042 ± 0.0669 | -0.008 ± 0.0492 | 0.050 ± 0.0577 | 0.025 ± 0.0354 |
| Phosphate, Day29, n= 6,12,6,4,2 | 0.052 ± 0.1488 | -0.010 ± 0.1123 | 0.023 ± 0.1472 | -0.073 ± 0.0562 | -0.050 ± 0.1131 |
| Phosphate, Day57, n= 5,12,6,4,2 | 0.052 ± 0.1657 | -0.064 ± 0.1072 | -0.025 ± 0.1088 | -0.058 ± 0.1250 | -0.020 ± 0.1556 |
| Phosphate, Day85, n= 6,12,6,4,2 | -0.020 ± 0.1942 | -0.003 ± 0.1342 | 0.055 ± 0.1001 | -0.008 ± 0.2017 | 0.080 ± 0.2546 |
| Phosphate, Day211, n= 6,12,6,4,2 | 0.023 ± 0.0528 | 0.056 ± 0.1800 | 0.005 ± 0.1401 | -0.018 ± 0.1231 | -0.130 ± 0.1273 |
| Potassium, Day29, n= 6,12,6,4,2 | 0.08 ± 0.248 | 0.16 ± 0.215 | 0.12 ± 0.458 | -0.05 ± 0.289 | 0.00 ± 0.141 |
| Potassium, Day57, n= 5,12,6,4,2 | 0.08 ± 0.335 | 0.27 ± 0.161 | 0.08 ± 0.293 | 0.03 ± 0.206 | -0.05 ± 0.354 |
| Potassium, Day85, n= 6,12,6,4,2 | 0.07 ± 0.151 | 0.37 ± 0.183 | 0.20 ± 0.210 | 0.00 ± 0.476 | 0.00 ± 0.566 |
| Potassium, Day211, n= 6,12,6,4,2 | 0.03 ± 0.367 | 0.31 ± 0.284 | 0.30 ± 0.228 | 0.23 ± 0.299 | 0.05 ± 0.919 |
| Sodium, Day29, n= 6,12,6,4,2 | 0.2 ± 0.75 | 0.2 ± 2.33 | 0.7 ± 2.42 | -1.0 ± 2.16 | -1.5 ± 0.71 |
| Sodium, Day57, n= 5,12,6,4,2 | -1.0 ± 1.87 | -0.2 ± 2.21 | -0.2 ± 1.47 | -0.5 ± 1.29 | -1.0 ± 0.00 |
| Sodium, Day85, n= 6,12,6,4,2 | -0.3 ± 2.16 | 0.5 ± 2.28 | 0.2 ± 1.72 | -0.8 ± 1.71 | -2.0 ± 1.41 |
| Sodium, Day211, n= 6,12,6,4,2 | -0.5 ± 2.35 | -0.3 ± 1.96 | 0.2 ± 1.94 | 0.3 ± 0.50 | -1.0 ± 0.00 |
| Urate, Day29, n= 6,12,6,4,2 | 0.0310 ± 0.05007 | 0.0248 ± 0.04039 | -0.0127 ± 0.01127 | -0.0060 ± 0.02728 | 0.0355 ± 0.04172 |
| Urate, Day57, n= 5,12,6,4,2 | 0.0192 ± 0.03713 | 0.0119 ± 0.05856 | -0.0158 ± 0.02260 | -0.0043 ± 0.04377 | 0.0030 ± 0.00424 |
| Urate, Day85, n= 6,12,6,4,2 | 0.0168 ± 0.04298 | -0.0061 ± 0.04391 | -0.0100 ± 0.02592 | -0.0078 ± 0.04984 | 0.0440 ± 0.02121 |
| Urate, Day211, n= 6,12,6,4,2 | 0.0012 ± 0.03783 | -0.0005 ± 0.05949 | -0.0128 ± 0.04086 | 0.0370 ± 0.02599 | 0.0325 ± 0.02899 |
| BUN, Day29, n= 6,12,6,4,2 | 0.417 ± 1.0192 | 0.356 ± 0.5040 | 0.415 ± 0.6125 | 0.180 ± 0.8980 | 0.355 ± 1.0112 |
| BUN, Day57, n= 5,12,6,4,2 | 0.788 ± 0.9903 | 0.238 ± 0.7960 | 0.535 ± 1.1451 | 0.980 ± 1.5543 | 0.180 ± 0.2546 |
| BUN, Day85, n= 6,12,6,4,2 | -0.177 ± 0.9241 | -0.059 ± 0.8974 | 0.833 ± 0.7011 | 0.000 ± 1.2040 | 0.000 ± 0.5091 |
| BUN, Day211, n= 6,12,6,4,2 | 0.358 ± 1.2580 | -0.208 ± 1.0941 | 0.713 ± 1.1510 | 0.893 ± 1.4463 | 0.000 ± 0.0000 |
Blood samples were collected for the analysis of clinical chemistry parameters: direct bilirubin, total bilirubin, indirect bilirubin and creatinine. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Micromoles per liter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Total Bilirubin, Day29, n= 6,12,6,4,2 | -1.72 ± 2.699 | -1.07 ± 2.529 | -1.92 ± 2.497 | -1.53 ± 3.497 | 1.40 ± 1.414 |
| Total Bilirubin, Day57, n= 5,12,6,4,2 | -2.14 ± 2.105 | -0.40 ± 3.930 | -1.72 ± 1.216 | -0.33 ± 3.802 | 3.85 ± 6.576 |
| Total Bilirubin, Day85, n= 6,12,6,4,2 | -1.47 ± 2.151 | -0.78 ± 2.840 | -1.52 ± 3.411 | -0.78 ± 2.290 | 5.40 ± 7.071 |
| Total Bilirubin, Day211, n= 6,12,6,4,2 | -0.87 ± 2.608 | -0.87 ± 3.538 | 0.40 ± 5.907 | 1.00 ± 2.432 | 2.75 ± 4.738 |
| Direct Bilirubin, Day29, n= 6,12,6,4,2 | 0.00 ± 0.000 | -0.02 ± 0.061 | 0.02 ± 0.041 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Direct Bilirubin, Day57, n= 5,12,6,4,2 | 0.00 ± 0.000 | -0.02 ± 0.061 | -0.07 ± 0.167 | 0.05 ± 0.105 | 0.00 ± 0.000 |
| Direct Bilirubin, Day85, n= 6,12,6,4,2 | 0.00 ± 0.000 | -0.02 ± 0.061 | -0.07 ± 0.167 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Direct Bilirubin, Day211, n= 6,12,6,4,2 | 0.00 ± 0.000 | -0.02 ± 0.061 | 0.05 ± 0.122 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Indirect Bilirubin, Day29, n= 0,0,1,0,0 | — | — | -0.60 ± NA | — | — |
| Indirect Bilirubin, Day211, n= 0,0,1,0,0 | — | — | 10.50 ± NA | — | — |
| Creatinine, Day29, n= 6,12,6,4,2 | 3.8 ± 3.39 | 7.8 ± 4.37 | -0.3 ± 7.00 | 8.8 ± 5.89 | 2.3 ± 3.18 |
| Creatinine, Day57, n= 5,12,6,4,2 | 2.7 ± 5.13 | 5.5 ± 6.53 | 2.5 ± 5.08 | 2.3 ± 12.18 | 2.3 ± 9.55 |
| Creatinine, Day85, n= 6,12,6,4,2 | 0.8 ± 8.73 | 3.9 ± 6.46 | 1.0 ± 5.67 | 2.0 ± 5.43 | 2.3 ± 3.18 |
| Creatinine, Day211, n= 6,12,6,4,2 | 0.8 ± 6.62 | 4.0 ± 8.82 | 4.0 ± 6.82 | 2.0 ± 5.43 | 6.8 ± 3.18 |
Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, WBC, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| 10^9 cells per liters | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Basophils, Day 29 | 0.00 ± 0.000 | 0.01 ± 0.029 | 0.00 ± 0.000 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Basophils, Day 57 | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Basophils, Day 85 | -0.02 ± 0.041 | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Basophils, Day 211 | 0.00 ± 0.000 | 0.01 ± 0.029 | 0.00 ± 0.000 | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Eosinophils, Day 29 | 0.03 ± 0.103 | -0.02 ± 0.103 | 0.03 ± 0.052 | 0.00 ± 0.082 | 0.00 ± 0.000 |
| Eosinophils, Day 57 | -0.02 ± 0.098 | -0.03 ± 0.115 | 0.05 ± 0.084 | 0.00 ± 0.082 | -0.10 ± 0.000 |
| Eosinophils, Day 85 | 0.08 ± 0.172 | -0.03 ± 0.115 | 0.02 ± 0.075 | -0.03 ± 0.126 | -0.05 ± 0.071 |
| Eosinophils, Day 211 | 0.10 ± 0.110 | -0.04 ± 0.108 | 0.03 ± 0.052 | 0.05 ± 0.058 | 0.05 ± 0.071 |
| WBC, Day 29 | -0.18 ± 1.206 | -0.60 ± 0.921 | -0.12 ± 0.826 | 0.28 ± 0.624 | -1.15 ± 0.212 |
| WBC, Day 57 | -0.33 ± 1.172 | -0.49 ± 0.958 | -0.37 ± 1.204 | 0.08 ± 0.222 | -0.95 ± 0.636 |
| WBC, Day 85 | -0.58 ± 1.177 | -0.63 ± 0.796 | -0.65 ± 0.814 | 0.43 ± 0.556 | -1.05 ± 0.071 |
| WBC, Day 211 | -0.45 ± 1.067 | 0.01 ± 0.696 | 0.10 ± 1.834 | 0.70 ± 0.589 | -0.85 ± 0.212 |
| Lymphocytes, Day 29 | -0.10 ± 0.219 | -0.27 ± 0.293 | -0.03 ± 0.294 | -0.10 ± 0.216 | 0.20 ± 0.283 |
| Lymphocytes Day 57 | 0.00 ± 0.200 | -0.15 ± 0.275 | -0.10 ± 0.456 | -0.05 ± 0.100 | -0.05 ± 0.071 |
| Lymphocytes, Day 85 | 0.17 ± 0.288 | -0.13 ± 0.273 | -0.03 ± 0.258 | 0.10 ± 0.294 | -0.10 ± 0.000 |
| Lymphocytes, Day 211 | 0.17 ± 0.301 | -0.11 ± 0.334 | -0.07 ± 0.234 | 0.15 ± 0.208 | -0.10 ± 0.141 |
| Neutrophils, Day 29 | -0.17 ± 1.027 | -0.36 ± 0.945 | -0.17 ± 0.706 | 0.30 ± 0.392 | -1.05 ± 0.212 |
| Neutrophils, Day 57 | -0.30 ± 1.075 | -0.31 ± 0.898 | -0.32 ± 1.301 | 0.13 ± 0.275 | -0.60 ± 0.849 |
| Neutrophils, Day 85 | -0.95 ± 0.812 | -0.45 ± 1.026 | -0.67 ± 0.585 | 0.35 ± 0.342 | -0.65 ± 0.212 |
| Neutrophils, Day 211 | -0.75 ± 0.873 | 0.18 ± 0.725 | 0.08 ± 1.967 | 0.48 ± 0.377 | -0.55 ± 0.212 |
| Monocytes, Day 29 | 0.08 ± 0.117 | -0.01 ± 0.138 | 0.02 ± 0.098 | 0.08 ± 0.050 | -0.25 ± 0.212 |
| Monocytes, Day 57 | 0.00 ± 0.089 | -0.01 ± 0.131 | 0.00 ± 0.167 | 0.03 ± 0.096 | -0.15 ± 0.354 |
| Monocytes, Day 85 | 0.08 ± 0.075 | -0.04 ± 0.124 | 0.03 ± 0.082 | 0.03 ± 0.050 | -0.20 ± 0.283 |
| Monocytes, Day 211 | 0.07 ± 0.103 | -0.05 ± 0.100 | 0.02 ± 0.075 | 0.10 ± 0.115 | -0.15 ± 0.212 |
| Platelets, Day 29 | -0.5 ± 23.87 | -8.3 ± 17.23 | 11.0 ± 21.94 | 18.0 ± 32.28 | 16.0 ± 9.90 |
| Platelets, Day 57 | -2.5 ± 26.76 | -8.3 ± 31.77 | 9.7 ± 37.08 | -7.5 ± 8.70 | 24.5 ± 17.68 |
| Platelets, Day 85 | -5.2 ± 31.92 | -8.3 ± 29.59 | 22.2 ± 27.95 | 1.5 ± 7.14 | 14.5 ± 40.31 |
| Platelets, Day 211 | 12.3 ± 22.81 | 4.6 ± 43.15 | 25.8 ± 20.49 | 17.3 ± 20.52 | -4.5 ± 44.55 |
Blood samples were collected for the analysis of hematology parameters including hemoglobin at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Grams per liter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | -7.3 ± 3.50 | -6.8 ± 8.74 | -11.3 ± 7.31 | -6.0 ± 6.48 | -11.5 ± 2.12 |
| Day 57 | -3.3 ± 10.25 | -3.0 ± 10.79 | -5.8 ± 9.28 | -3.8 ± 6.95 | -3.5 ± 4.95 |
| Day 85 | -4.0 ± 10.60 | -4.8 ± 13.13 | -9.2 ± 10.07 | -0.3 ± 3.86 | -5.0 ± 9.90 |
| Day 211 | -0.7 ± 15.73 | 1.8 ± 16.68 | -7.5 ± 6.47 | 4.8 ± 5.19 | 0.0 ± 1.41 |
Blood samples were collected for the analysis of hematology parameter including hematocrit at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Percentage of red blood cells in blood | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | -2.47 ± 1.150 | -2.39 ± 2.858 | -4.20 ± 2.577 | -2.23 ± 2.089 | -3.30 ± 0.283 |
| Day 57 | -1.17 ± 2.630 | -1.04 ± 3.089 | -2.17 ± 3.080 | -1.10 ± 2.482 | -0.80 ± 2.546 |
| Day 85 | -1.33 ± 3.043 | -0.98 ± 3.698 | -3.13 ± 2.501 | -0.28 ± 1.646 | -1.65 ± 3.748 |
| Day 211 | -0.37 ± 4.065 | 1.53 ± 4.799 | -1.83 ± 2.066 | 1.40 ± 1.930 | 1.05 ± 1.768 |
Urine samples were collected for the analysis of urine specific gravity. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value. Urine specific gravity is measured as the ratio of urine density compared with water density.
| Ratio of urine to water density | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | -0.0017 ± 0.00703 | 0.0033 ± 0.00585 | 0.0032 ± 0.00523 | 0.0028 ± 0.00427 | 0.0080 ± 0.00566 |
| Day 57 | 0.0000 ± 0.00832 | 0.0059 ± 0.00763 | 0.0028 ± 0.00519 | 0.0038 ± 0.00457 | 0.0130 ± 0.00141 |
| Day 85 | -0.0007 ± 0.00653 | 0.0020 ± 0.00481 | 0.0057 ± 0.00441 | 0.0013 ± 0.00450 | 0.0130 ± 0.00000 |
| Day 211 | -0.0020 ± 0.00851 | 0.0024 ± 0.00684 | 0.0010 ± 0.00522 | -0.0005 ± 0.00387 | 0.0060 ± 0.00849 |
Urine samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Milligrams per millimole Creatinine | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Urine albumin/creatinine ratio, Day29,n=0,1,0,0,0 | — | -3.340 ± NA | — | — | — |
| Urine albumin/creatinine ratio, Day57,n=0,2,0,0,0 | — | -10.580 ± 10.9743 | — | — | — |
| Urine albumin/creatinine ratio, Day85,n=0,1,1,0,0 | — | -3.480 ± NA | 0.080 ± NA | — | — |
| Urine protein/creatinine ratio Day29, n=5,10,4,4,2 | 0.006 ± 0.0329 | -0.002 ± 0.1264 | -0.005 ± 0.0058 | 0.065 ± 0.0238 | 0.025 ± 0.0071 |
| Urine protein/creatinine ratio Day57, n=6,9,3,4,2 | -0.007 ± 0.0589 | -0.043 ± 0.1168 | -0.003 ± 0.0058 | 0.020 ± 0.0000 | 0.010 ± 0.0000 |
| Urine protein/creatinine ratio Day85, n=6,8,4,3,2 | -0.003 ± 0.0554 | -0.050 ± 0.1042 | -0.005 ± 0.0129 | 0.017 ± 0.0231 | 0.000 ± 0.0141 |
| Urine protein/creatinine ratio Day211, n=4,8,4,3,1 | 0.003 ± 0.0150 | -0.073 ± 0.1235 | -0.005 ± 0.0311 | 0.013 ± 0.0252 | 0.000 ± NA |
Urine samples were collected for the analysis of urine protein. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Milligrams per deciliter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | -1.08 ± 7.591 | 7.06 ± 5.130 | -0.51 ± 2.605 | 11.13 ± 9.288 | 3.76 ± 5.020 |
| Day 57 | -2.57 ± 7.451 | 5.62 ± 7.910 | 2.00 ± 5.903 | 4.48 ± 3.502 | 5.56 ± 3.889 |
| Day 85 | -2.07 ± 5.814 | 1.45 ± 3.747 | 2.29 ± 2.267 | 2.48 ± 3.954 | 4.01 ± 0.283 |
| Day 211 | -2.29 ± 7.277 | 0.90 ± 2.832 | -0.46 ± 2.214 | 0.90 ± 1.664 | 2.71 ± 3.8250 |
Blood samples were collected for the analysis of blood coagulation factors:activated partial thromboplastin time (aPTT) and Prothrombin Time (PT). Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Seconds | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| aPTT, Day 23, n=5,11,6,4,2 | -2.44 ± 4.017 | -2.33 ± 6.460 | -1.63 ± 1.715 | -0.45 ± 1.808 | 0.65 ± 0.778 |
| aPTT, Day 57, n=6,12,5,4,2 | 1.23 ± 3.518 | -3.03 ± 5.854 | -0.18 ± 3.841 | 0.13 ± 3.627 | -0.35 ± 1.344 |
| aPTT, Day 85, n=0,0,0,1,0 | — | — | — | 0.00 ± NA | — |
| aPTT, Day 211, n=5,11,6,2,2 | 1.28 ± 6.538 | -1.01 ± 6.310 | 2.70 ± 3.046 | 1.30 ± 4.384 | 2.60 ± 3.394 |
| PT, Day 23, n=5,11,6,4,2 | -0.42 ± 0.576 | -0.23 ± 0.710 | 0.12 ± 0.483 | 0.33 ± 0.585 | 0.60 ± 0.141 |
| PT, Day 57, n=6,12,5,4,2 | -0.10 ± 0.740 | -0.50 ± 0.615 | 0.20 ± 0.869 | -0.18 ± 0.780 | 0.40 ± 0.141 |
| PT, Day85, n=0,0,0,1,0 | — | — | — | -0.80 ± NA | — |
| PT, Day211, n=5,11,6,2,2 | -0.84 ± 0.623 | -0.35 ± 0.726 | 0.42 ± 0.744 | 0.45 ± 0.919 | 0.70 ± 0.283 |
Blood samples were collected for the analysis of blood coagulation factor: Prothrombin International normalized ratio. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Ratio | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 23, n=5,11,6,4,2 | -0.04 ± 0.055 | -0.04 ± 0.067 | 0.02 ± 0.041 | 0.03 ± 0.096 | 0.00 ± 0.000 |
| Day 57, n=6,12,5,4,2 | -0.02 ± 0.075 | -0.04 ± 0.079 | 0.02 ± 0.084 | 0.00 ± 0.082 | 0.00 ± 0.000 |
| Day 85, n=0,0,0,1,0 | — | — | — | 0.00 ± NA | — |
| Day 211, n=5,11,6,2,2 | -0.06 ± 0.089 | -0.03 ± 0.079 | 0.02 ± 0.075 | 0.05 ± 0.071 | 0.00 ± 0.000 |
Blood samples were collected from participants to evaluate change in complement C3 level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement C3 was the minimum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Milligram per deciliter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change in Complement C3 Level at Worst Case Post Baseline Relative to Baseline | -19.8 ± 11.72 | -22.3 ± 12.00 | -16.5 ± 13.81 | -12.4 ± 3.78 | -25.5 ± 16.26 |
Blood samples were collected from participants to evaluate change in complement C5a level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement C5a was the maximum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Nanogram per milliliter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change in Complement C5a Level at Worst Case Post Baseline Relative to Baseline | 1.552 ± 1.3967 | 3.778 ± 6.2062 | 1.303 ± 0.8671 | 2.232 ± 2.2640 | 0.800 ± 0.0000 |
Blood samples were collected from participants to evaluate change in complement Bb level at worst case post Baseline relative to Baseline. Worst case post Baseline in Complement Bb was the maximum post-Baseline level. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Microgram per milliliter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change in Complement Bb Level at Worst Case Post Baseline Relative to Baseline | 0.355 ± 0.1129 | 0.365 ± 0.4835 | 0.240 ± 0.3543 | 0.472 ± 0.1439 | 0.320 ± 0.3677 |
Female participants who were not surgically sterile or post-menopausal, underwent urine beta Human chorionic gonadotropin (Beta-HCG) pregnancy test.
| Participants | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Number of Participants With Reported Pregnancy | 0 | 0 | 0 | 0 | 0 |
Body temperature was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Degrees Celsius | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | -0.05 ± 0.288 | -0.09 ± 0.353 | -0.15 ± 0.164 | 0.08 ± 0.250 | 0.30 ± 0.141 |
| Day 57 | 0.03 ± 0.294 | -0.16 ± 0.342 | -0.18 ± 0.248 | 0.48 ± 0.096 | 0.20 ± 0.849 |
| Day 85 | 0.05 ± 0.451 | -0.18 ± 0.290 | -0.13 ± 0.103 | 0.10 ± 0.115 | -0.20 ± 0.707 |
| Day 211 | -0.20 ± 0.210 | -0.19 ± 0.291 | -0.17 ± 0.216 | 0.23 ± 0.369 | -0.10 ± 0.424 |
Body weight was measured at indicated time points. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Kilograms | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | -0.48 ± 3.406 | 0.20 ± 0.802 | 0.52 ± 0.786 | 0.00 ± 0.808 | -1.25 ± 0.636 |
| Day 57 | -0.40 ± 3.992 | -0.10 ± 1.834 | -0.18 ± 1.009 | 0.20 ± 1.214 | -0.25 ± 0.354 |
| Day 211 | -0.15 ± 3.627 | -0.40 ± 2.721 | -0.37 ± 1.350 | 2.00 ± 1.212 | 1.95 ± 0.354 |
Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Millimeters of Mercury (mmHg) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| SBP, Day 29 | -6.3 ± 13.76 | -8.8 ± 12.05 | -9.2 ± 10.11 | -3.0 ± 6.63 | 0.5 ± 9.19 |
| SBP, Day 57 | 3.7 ± 11.33 | -3.4 ± 13.98 | -13.2 ± 5.31 | 7.8 ± 7.93 | -2.0 ± 5.66 |
| SBP, Day 85 | 3.0 ± 12.44 | -5.4 ± 13.45 | -13.7 ± 7.99 | 4.3 ± 8.58 | 6.5 ± 13.44 |
| SBP, Day 211 | 10.0 ± 13.49 | -3.6 ± 15.21 | -10.2 ± 5.19 | 7.3 ± 10.21 | 5.0 ± 9.90 |
| DBP, Day 29 | -4.0 ± 8.65 | -2.2 ± 7.77 | -6.0 ± 5.73 | -5.0 ± 7.26 | -0.5 ± 9.19 |
| DBP, Day 57 | 1.0 ± 8.20 | -0.2 ± 9.92 | -3.0 ± 11.06 | 0.0 ± 9.38 | 3.0 ± 4.24 |
| DBP, Day 85 | 2.2 ± 6.71 | 0.1 ± 12.43 | -3.7 ± 6.65 | -1.8 ± 6.08 | 4.5 ± 14.85 |
| DBP, Day 211 | 6.8 ± 6.37 | 0.8 ± 9.88 | -3.8 ± 9.56 | 4.3 ± 6.95 | 8.0 ± 8.49 |
Respiratory Rate was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Breaths/minute | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | 0.3 ± 1.03 | 0.7 ± 0.65 | 0.3 ± 0.52 | -0.8 ± 2.22 | -2.5 ± 2.12 |
| Day 57 | -0.5 ± 1.87 | 0.6 ± 0.67 | 0.2 ± 1.33 | -0.8 ± 2.22 | -2.5 ± 2.12 |
| Day 85 | -0.3 ± 1.86 | 0.5 ± 0.52 | 0.2 ± 0.41 | -0.8 ± 2.22 | -3.0 ± 1.41 |
| Day 211 | -0.5 ± 1.97 | 0.7 ± 0.78 | 0.0 ± 0.10 | -1.0 ± 2.00 | -3.0 ± 1.41 |
Pulse Rate was measured at indicated timepoints. Baseline value is defined as last non-missing measurement prior to the first dose of study drug. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Beats/minute | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | -4.7 ± 13.63 | 4.3 ± 8.14 | 1.5 ± 5.32 | 9.0 ± 6.63 | 1.0 ± 4.24 |
| Day 57 | -1.5 ± 16.34 | 8.2 ± 14.33 | 6.5 ± 14.36 | 16.0 ± 6.06 | 8.0 ± 4.24 |
| Day 85 | 5.7 ± 19.96 | 2.3 ± 9.10 | -1.7 ± 7.15 | 16.8 ± 5.32 | 3.5 ± 7.78 |
| Day 211 | -0.3 ± 18.82 | 2.9 ± 8.70 | 1.8 ± 12.22 | 16.3 ± 8.42 | 13.0 ± 2.83 |
Physical examinations included assessment of the dermatologic, cardiovascular, respiratory, gastrointestinal, and neurological systems.
| Participants | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Number of Participants With Abnormal Findings in Physical Examination | 3 | 1 | 1 | 0 | 0 |
A concomitant medication is defined as any medication initiated after the first dose of study, or initiated prior to the first dose of study drug and continued after the first dose of study drug.
| Participants | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Number of Participants Who Received Atleast One Concomitant Medication | 4 | 8 | 5 | 5 | 2 |
Triplicate 12-lead Electrocardiograms (ECGs) were recorded at indicated timepoints. At each time point, ECG machine automatically measured mean ventricular rate (VR). Baseline ECG was the average of the triplicate taken on Day 1 Pre-dose, if only 1 or 2 assessments were available, the single assessment or average of the 2 assessments was used. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Beats per minute | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Mean VR, Day1, 3 hours Post-dose, n=6,12,6,5,2 | 4.3 ± 5.05 | 5.6 ± 8.85 | 4.5 ± 4.93 | 8.2 ± 4.60 | 10.0 ± 2.83 |
| Mean VR, Day1, 5 hours Post-dose, n=6,12,6,5,2 | 1.8 ± 6.52 | 2.0 ± 7.93 | 4.7 ± 6.22 | 12.6 ± 6.88 | 8.0 ± 9.90 |
| Mean VR, Day 2, n=6,12,6,5,2 | -2.7 ± 10.27 | 10.1 ± 12.93 | 0.3 ± 2.66 | 22.8 ± 9.15 | 5.5 ± 7.78 |
| Mean VR, Day 22, Pre-dose, n=5,12,6,4,2 | -3.6 ± 5.46 | 0.4 ± 8.54 | 1.0 ± 6.54 | 0.8 ± 4.86 | -1.0 ± 5.66 |
| Mean VR, Day 22, 3 hours Post-dose, n=5,12,6,4,2 | -1.4 ± 7.37 | 5.0 ± 7.24 | 3.7 ± 5.47 | 9.3 ± 4.92 | 8.5 ± 2.12 |
| Mean VR, Day 22, 5 hours Post-dose, n=5,12,6,4,2 | -1.8 ± 10.47 | 3.4 ± 6.27 | -0.7 ± 5.82 | 8.0 ± 6.22 | 8.0 ± 2.83 |
| Mean VR, Day 23, n=5,12,6,4,2 | -2.4 ± 8.26 | 6.3 ± 3.65 | 1.3 ± 4.76 | 10.3 ± 4.92 | 0.0 ± 4.24 |
| Mean VR, Day 29, n=6,12,6,4,2 | -1.3 ± 11.60 | 2.8 ± 7.63 | 0.2 ± 4.45 | 7.3 ± 6.13 | 3.5 ± 7.78 |
| Mean VR, Day 113, n=6,12,6,4,2 | -5.2 ± 9.75 | 2.5 ± 10.60 | -2.3 ± 6.06 | 8.3 ± 2.06 | 8.0 ± 9.90 |
Triplicate 12-lead Electrocardiograms (ECGs) were recorded at indicated timepoints. At each time point, ECG machine automatically measured QRS duration, uncorrected QT interval, QT corrected interval-Fredericia \[QTcF\] interval and QTc corrected by Bazett's formula (QTcB). Baseline ECG was the average of the triplicate taken on Day 1 Pre-dose, if only 1 or 2 assessments were available, the single assessment or average of the 2 assessments was used. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Milliseconds | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| PR, Day 1,3 hours Post-dose, n=6,11,6,5,2 | -1.2 ± 8.42 | 1.8 ± 9.99 | 3.5 ± 30.84 | 0.8 ± 8.41 | 7.0 ± 1.41 |
| PR, Day 1, 5 hours Post-dose, n=6,11,6,5,2 | -1.7 ± 8.64 | 1.3 ± 8.37 | 10.8 ± 33.52 | 1.4 ± 8.38 | -3.0 ± 0.00 |
| PR, Day 2, n=6,12,6,5,2 | 1.0 ± 4.65 | 0.7 ± 15.78 | 12.2 ± 21.45 | -2.4 ± 8.79 | 5.5 ± 2.12 |
| PR, Day 22, Pre-dose, n=5,12,6,4,2 | 7.0 ± 14.27 | -2.4 ± 11.70 | 11.0 ± 19.84 | -2.8 ± 10.87 | 8.0 ± 7.07 |
| PR, Day 22, 3 hours Post-dose, n=5,12,6,4,2 | 2.0 ± 7.21 | 0.3 ± 14.51 | 9.2 ± 21.51 | -6.5 ± 11.79 | 7.5 ± 6.36 |
| PR, Day 22, 5 hours Post-dose, n=5,11,6,4,2 | -0.2 ± 10.03 | -2.3 ± 14.18 | 9.0 ± 22.82 | -7.0 ± 9.42 | 5.5 ± 4.95 |
| PR, Day 23, n=5,11,6,4,2 | 9.4 ± 12.03 | -1.6 ± 11.09 | 11.2 ± 21.77 | -1.0 ± 7.79 | 4.5 ± 3.54 |
| PR, Day 29, n=6,12,6,4,2 | 4.8 ± 7.28 | -1.7 ± 11.67 | 7.3 ± 17.64 | -1.8 ± 4.72 | 10.0 ± 4.24 |
| PR, Day 113, n=6,12,6,4,2 | 7.7 ± 8.82 | -1.6 ± 14.48 | 14.3 ± 21.81 | -2.0 ± 8.83 | 6.0 ± 7.07 |
| QRS duration, Day1, 3 hours Post-dose,n=6,12,6,5,2 | 0.8 ± 3.97 | -0.2 ± 5.08 | 2.2 ± 4.31 | 1.0 ± 2.00 | -1.5 ± 3.54 |
| QRS duration, Day1, 5 hours Post-dose,n=6,12,6,5,2 | -0.8 ± 2.04 | -1.7 ± 4.38 | 6.0 ± 4.98 | 0.4 ± 1.95 | -3.0 ± 4.24 |
| QRS duration, Day 2, n=6,12,6,5,2 | 0.5 ± 3.94 | 0.8 ± 3.98 | 3.7 ± 8.07 | -2.2 ± 4.87 | -0.5 ± 0.71 |
| QRS duration, Day 22, Pre-dose, n=5,12,6,4,2 | 0.2 ± 3.11 | -3.6 ± 5.07 | 4.2 ± 3.19 | -0.8 ± 4.79 | -4.0 ± 2.83 |
| QRS duration, Day 22, 3 hours Post-dose, n=5,12,6,4,2 | 1.6 ± 3.51 | -1.2 ± 4.11 | 5.0 ± 6.99 | 2.5 ± 1.91 | -1.0 ± 0.00 |
| QRS duration, Day 22, 5 hours Post-dose, n=5,12,6,4,2 | 1.0 ± 5.15 | -1.0 ± 3.86 | 6.3 ± 5.28 | -0.3 ± 5.12 | -2.0 ± 1.41 |
| QRS duration, Day 23, n=5,12,6,4,2 | -0.4 ± 5.37 | 0.9 ± 3.09 | 0.3 ± 7.00 | -0.5 ± 4.12 | 1.5 ± 3.54 |
| QRS duration, Day 29, n=6,12,6,4,2 | 0.3 ± 4.18 | 0.7 ± 4.91 | 5.5 ± 7.50 | 3.0 ± 6.98 | 0.5 ± 0.71 |
| QRS duration, Day 113, n=6,12,6,4,2 | 0.3 ± 5.72 | 0.0 ± 4.90 | 4.7 ± 8.09 | -2.8 ± 5.19 | 1.0 ± 1.41 |
| QT, Day 1, 3 hours Post-dose, n=6,12,6,5,2 | -11.8 ± 14.85 | -12.4 ± 17.30 | -5.7 ± 8.21 | -23.8 ± 9.55 | -20.5 ± 0.71 |
| QT, Day 1, 5 hours Post-dose, n=6,12,6,5,2 | -11.3 ± 19.41 | -10.3 ± 18.25 | -7.3 ± 12.80 | -37.6 ± 19.89 | -21.0 ± 11.31 |
| QT, Day 2, n=6,12,6,5,2 | -0.3 ± 29.34 | -25.5 ± 29.57 | 0.3 ± 6.41 | -62.8 ± 19.38 | 19.5 ± 19.09 |
| QT, Day 22, Pre-dose, n=5,12,6,4,2 | 15.2 ± 12.91 | 1.9 ± 17.05 | 2.0 ± 19.65 | -1.0 ± 12.68 | 3.0 ± 11.31 |
| QT, Day 22, 3 hours Post-dose, n=5,12,6,4,2 | 11.2 ± 30.60 | -8.7 ± 21.05 | -3.0 ± 17.31 | -27.3 ± 22.47 | -16.0 ± 12.73 |
| QT, Day 22, 5 hours Post-dose, n=5,12,6,4,2 | 5.8 ± 29.71 | -8.0 ± 18.68 | 2.5 ± 16.31 | -25.3 ± 23.73 | -17.5 ± 9.19 |
| QT, Day 23, n=5,12,6,4,2 | 8.0 ± 23.63 | -13.9 ± 13.81 | -5.2 ± 16.74 | -30.5 ± 18.81 | -8.5 ± 6.36 |
| QT, Day 29, n=6,12,6,4,2 | 9.0 ± 31.92 | -5.4 ± 20.97 | 2.5 ± 15.45 | -23.0 ± 16.02 | -4.0 ± 31.11 |
| QT, Day 113, n=6,12,6,4,2 | 13.7 ± 30.59 | -15.4 ± 49.82 | 4.2 ± 17.95 | -28.3 ± 13.33 | -20.0 ± 22.63 |
| QTcB, Day 1,3 hours Post-dose, n=1,3,2,0,0 | 5.0 ± NA | 3.3 ± 3.06 | 3.0 ± 1.41 | — | — |
| QTcB, Day 1, 5 hours Post-dose, n=1,3,2,0,0 | -9.0 ± NA | -1.3 ± 11.02 | 4.5 ± 0.71 | — | — |
| QTcB, Day 2, n=1,3,2,0,0 | -3.0 ± NA | 4.3 ± 7.57 | 2.5 ± 0.71 | — | — |
| QTcB, Day 22, Pre-dose, n=1,3,2,0,0 | 27.0 ± NA | 7.3 ± 6.43 | -0.5 ± 7.78 | — | — |
| QTcB, Day 22, 3 hours Post-dose, n=1,3,2,0,0 | 16.0 ± NA | 18.7 ± 16.77 | -2.0 ± 2.83 | — | — |
| QTcB, Day 22, 5 hours Post-dose, n=1,3,2,0,0 | 11.0 ± NA | 3.7 ± 2.31 | -14.5 ± 6.36 | — | — |
| QTcB, Day 23, n=1,3,2,0,0 | 14.0 ± NA | 7.3 ± 8.62 | -3.5 ± 7.78 | — | — |
| QTcB, Day 29, n=1,4,2,0,0 | 21.0 ± NA | 3.0 ± 8.98 | 6.5 ± 6.36 | — | — |
| QTcB, Day 113, n=1,5,3,0,0 | 5.0 ± NA | -1.8 ± 3.27 | -13.0 ± 8.54 | — | — |
| QTcF, Day 1,3 hours Post-dose, n=5,9,4,5,2 | -6.0 ± 6.28 | -1.9 ± 8.16 | 3.5 ± 7.05 | -3.8 ± 13.88 | -4.5 ± 4.95 |
| QTcF, Day 1,5 hours Post-dose, n=5,9,4,5,2 | -9.6 ± 10.67 | -8.9 ± 8.49 | 1.3 ± 5.32 | -9.0 ± 13.84 | -7.5 ± 6.36 |
| QTcF, Day 2, n=4,8,4,5,2 | -8.6 ± 13.50 | -12.5 ± 9.01 | -1.0 ± 4.69 | -44.6 ± 65.50 | -11.0 ± 5.66 |
| QTcF, Day 22, Pre-dose, n=5,9,4,4,2 | -1.0 ± 2.94 | 0.7 ± 12.19 | 8.8 ± 8.88 | 1.3 ± 3.77 | -1.5 ± 2.12 |
| QTcF, Day 22, 3 hours Post-dose, n=4,9,4,4,2 | 0.8 ± 10.08 | -1.0 ± 11.10 | 9.5 ± 10.47 | -4.5 ± 13.48 | -1.5 ± 10.61 |
| QTcF, Day 22, 5 hours Post-dose, n=4,9,4,5,2 | -5.0 ± 7.66 | -3.6 ± 12.97 | 5.8 ± 9.95 | -5.8 ± 12.55 | -4.5 ± 4.95 |
| QTcF, Day 23, n=4,8,4,4,2 | -0.8 ± 8.38 | -3.3 ± 9.82 | -0.5 ± 7.05 | -5.0 ± 9.20 | -10.0 ± 0.00 |
| QTcF, Day 29, n=5,8,4,4,2 | 4.0 ± 22.55 | -0.1 ± 9.60 | 3.0 ± 8.98 | -5.5 ± 10.08 | -4.5 ± 10.61 |
| QTcF, Day 113, n=5,6,3,4,2 | -1.08 ± 20.24 | -1.0 ± 14.09 | 4.0 ± 12.29 | -6.5 ± 10.75 | -7.0 ± 5.66 |
Blood samples were collected from participants to assess HBV DNA viral load. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. The last observation carried forward (LOCF) method was used to impute missing values at Day 29 in this analysis.
| Log10 (International Units/milliliter) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Day 29 | -0.384 ± 0.4199 | -1.655 ± 1.4791 | -0.001 ± 0.4710 | 0.075 ± 0.1667 | 0.000 ± 0.0000 |
Blood samples were collected from participants to assess HBV DNA viral load. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Log10 (International Units/milliliter) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Viral Load in Plasma at Week 31 | -4.754 ± 0.8344 | -4.770 ± 1.2823 | -3.547 ± 1.2798 | 0.000 ± 0.0000 | 0.000 ± NA |
Blood samples were collected from participants to assess HBsAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. The LOCF method was used to impute missing values at Day 29 in this analysis.
| Log10 (International Units/milliliter) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change From Baseline in HBV Surface Antigen (HBsAg) Level in Serum at Day 29 | -0.504 ± 0.5656 | -1.556 ± 1.3787 | 0.000 ± 0.1116 | -1.986 ± 1.7986 | -0.008 ± 0.0390 |
Blood samples were collected from participants to assess HBsAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Log10 (International Units/milliliter) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change From Baseline in HBsAg Level in Serum at Week 31 | -0.523 ± 0.9299 | -0.547 ± 0.6109 | 0.059 ± 0.3859 | -1.519 ± 1.4821 | -0.043 ± 0.0178 |
Blood samples were collected to evaluate the percentage of participants with HBsAg loss at Day 29 and Week 31. A 'Loss' of HBsAg means antigen is negative. HBsAg Loss percentage is defined as number of participants with HBsAg loss divided by total number of participants assessed multiplied by 100. Baseline is the last non-missing measurement prior to the first dose of study drug.
| Percentage of Participants | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | 0 | 16.7 | 0 | 20.0 | 0 |
| Week 31 | 0 | 0 | 0 | 0 | 0 |
Blood samples were collected to evaluate the percentage of participants with HBeAg loss at Day 29 and Week 31. A 'Loss' of HBeAg means antigen is negative. HBeAg Loss percentage is defined as number of participants with HBeAg loss divided by number of participants with positive HBeAg at Baseline multiplied by 100. Baseline is the last non-missing measurement prior to the first dose of study drug. Participants was considered HBeAg positive at Baseline if the Baseline value\> 0.09 U/mL.
| Percentage of Participants | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Day 29 | 0 | 0 | 0 | — | — |
| Week 31 | 0 | 0 | 0 | — | — |
Blood samples were collected from participants to assess HBeAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. Participant was considered HBeAg positive at Baseline if the Baseline value\> 0.09 International Units/milliliter (IU/mL).
| Log10 (IU/mL) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Serum HBeAg Concentration at Day 29 in Participants Who Were HBeAg Positive at Baseline | -0.004 ± 0.3967 | -0.052 ± 0.6741 | 0.133 ± 0.2884 | — | — |
Blood samples were collected from participants to assess HBeAg level. Baseline is the last non-missing measurement prior to the first dose of study drug. The concentrations were logarithmic transformed with base 10 in this analysis. Change from Baseline is defined as post-dose visit value minus Baseline value. Participant was considered HBeAg positive at Baseline if the Baseline value\> 0.09 U/mL.
| Log10 IU/mL | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Serum HBeAg Concentration at Week 31 in Participants Who Were HBeAg Positive at Baseline | -0.577 ± 1.3711 | -0.195 ± 0.5047 | 0.131 ± 0.7477 | — | — |
Plasma samples were collected from participants with chronic HBV infection at indicated time points for pharmacokinetic analysis of GSK3228836.
| Nanogram per milliliter | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohort 4 GSK3228836 300 mg |
|---|---|---|---|
| Day 1, pre-dose, n=6,12,5 | 0.00 ± 0.000 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Day 1, 0.5 hour post-dose, n=6,12,5 | 1187.00 ± 1052.256 | 2145.58 ± 1295.533 | 1630.00 ± 539.583 |
| Day 1, 1 hour post-dose, n=6,11,5 | 1909.33 ± 1287.383 | 4950.91 ± 2025.302 | 4074.00 ± 1314.565 |
| Day 1, 1.5 hours post-dose, n=6,12,5 | 2440.00 ± 1515.823 | 6536.67 ± 2710.704 | 6100.00 ± 1816.631 |
| Day 1, 2 hours post-dose, n=6,12,5 | 2976.67 ± 1444.793 | 8387.50 ± 3287.981 | 7556.00 ± 2672.579 |
| Day 1, 3 hours post-dose, n=6,12,5 | 3360.00 ± 1614.955 | 9905.00 ± 3494.308 | 8916.00 ± 2541.324 |
| Day 1, 4 hours post-dose, n=6,12,5 | 3340.00 ± 1223.781 | 9658.33 ± 3612.189 | 9632.00 ± 2115.401 |
| Day 1, 5 hours post-dose, n=6,12,5 | 3210.00 ± 1156.962 | 9813.33 ± 3524.376 | 9122.00 ± 2616.662 |
| Day 1, 6 hours post-dose, n=6,12,5 | 2933.33 ± 986.097 | 9345.00 ± 3258.863 | 8580.00 ± 2203.418 |
| Day 2, 24 hours post dose, n=6,12,5 | 112.22 ± 79.406 | 336.88 ± 301.302 | 356.00 ± 140.490 |
| Day 4 , 72 hours post-dose, n=6,12,5 | 6.77 ± 2.759 | 12.92 ± 3.975 | 15.24 ± 3.138 |
| Day 8, pre-dose, n=6,12,4 | 7.69 ± 4.540 | 22.07 ± 7.715 | 21.80 ± 6.458 |
| Day 15, pre-dose, n=6,12,4 | 10.90 ± 4.989 | 30.29 ± 12.598 | 33.33 ± 11.536 |
| Day 22, pre-dose, n=5,12,4 | 9.38 ± 2.279 | 22.85 ± 9.848 | 25.43 ± 7.630 |
| Day 22 0.5 hour pre-dose, n=5,12,4 | 1315.40 ± 1064.380 | 2073.58 ± 883.806 | 1447.75 ± 850.592 |
| Day 22, 1 hour post-dose, n=5,12,4 | 2133.00 ± 1616.738 | 4815.83 ± 1835.595 | 3477.50 ± 2009.766 |
| Day 22, 1.5 hours post-dose, n=5,12,4 | 2874.00 ± 1872.173 | 7094.17 ± 2862.178 | 5235.00 ± 3036.341 |
| Day 22, 2 hours post-dose, n=5,12,4 | 3466.00 ± 2033.158 | 8351.67 ± 3274.596 | 6765.00 ± 3805.422 |
| Day 22, 3 hours post-dose, n=5,12,4 | 4070.00 ± 2146.742 | 9137.50 ± 3303.139 | 8325.00 ± 5007.950 |
| Day 22, 4 hours post-dose, n=5,12,4 | 3760.00 ± 1572.260 | 8650.00 ± 2913.339 | 8690.00 ± 4808.791 |
| Day 22, 5 hours post-dose, n=5,12,4 | 3566.00 ± 1229.504 | 8072.50 ± 2748.322 | 8027.50 ± 4274.166 |
| Day 22, 6 hours post-dose, n=5,12,4 | 2990.00 ± 817.099 | 7769.17 ± 2295.697 | 7447.50 ± 3817.376 |
| Day 23, 24 hours post-dose, n=5,12,4 | 152.90 ± 148.879 | 387.88 ± 209.944 | 524.00 ± 372.305 |
| Day 29, n=5,12,4 | 8.88 ± 1.680 | 23.42 ± 9.358 | 21.50 ± 4.883 |
| Day 36, n=5,12,4 | 5.32 ± 1.098 | 12.58 ± 6.332 | 8.96 ± 3.246 |
| Day 57, n=5,12,4 | 1.91 ± 0.405 | 3.80 ± 1.294 | 1.90 ± 0.752 |
| Day 85, n=5,12,4 | 0.00 ± 0.00 | 1.32 ± 0.872 | 0.31 ± 0.625 |
| Day 133, n=5,12,4 | 0.91 ± 1.273 | 0.59 ± 0.619 | 0.00 ± 0.00 |
| Day 211, n=5,12,4 | 0.38 ± 0.845 | 1.04 ± 2.438 | 0.37 ± 0.730 |
Collected over Non-serious (>=5%) and serious adverse events were collected up to Day 211. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 GSK3228836 150 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 2 and Cohort 3 GSK3228836 300 mg | 0/12 (0%) | 1/12 (8.3%) | 6/12 (50%) |
| Cohorts 1-3 Placebo | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Cohort 4 GSK3228836 300 mg | 0/5 (0%) | 0/5 (0%) | 3/5 (60%) |
| Cohort 4 Placebo | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/6 | 1/12 | 0/6 | 0/5 | 0/2 |
| Event | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo |
|---|---|---|---|---|---|
| Injection site pruritusGeneral disorders | 2/6 | 1/12 | 0/6 | 0/5 | 0/2 |
| Injection site erythemaGeneral disorders | 0/6 | 3/12 | 0/6 | 1/5 | 0/2 |
| PyrexiaGeneral disorders | 1/6 | 3/12 | 1/6 | 1/5 | 0/2 |
| Injection site bruisingGeneral disorders | 1/6 | 0/12 | 0/6 | 1/5 | 0/2 |
| Injection site swellingGeneral disorders | 0/6 | 2/12 | 0/6 | 1/5 | 0/2 |
| Injection site painGeneral disorders | 1/6 | 1/12 | 0/6 | 0/5 | 0/2 |
| Injection site rashGeneral disorders | 1/6 | 0/12 | 0/6 | 0/5 | 0/2 |
| Abdominal discomfortGastrointestinal disorders | 1/6 | 0/12 | 0/6 | 0/5 | 0/2 |
| Mouth swellingGastrointestinal disorders | 1/6 | 0/12 | 0/6 | 0/5 | 0/2 |
| NauseaGastrointestinal disorders | 1/6 | 2/12 | 1/6 | 0/5 | 0/2 |
In Cohort 3 participants were administered GSK3228836 300 mg instead of 450 mg as per sponsor's decision, hence Cohort 2 and Cohort 3 have been combined.
| Age, Continuous(Years) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 42.5 ± 11.22 | 42.6 ± 14.12 | 49.3 ± 12.66 | 48.4 ± 7.40 | 37.0 ± 2.83 | 44.5 ± 11.90 |
| Sex: Female, Male(Participants) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 8 | 2 | 1 | 1 | 15 |
| Male | 3 | 4 | 4 | 4 | 1 | 16 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 GSK3228836 150 mg | Cohort 2 and Cohort 3 GSK3228836 300 mg | Cohorts 1-3 Placebo | Cohort 4 GSK3228836 300 mg | Cohort 4 Placebo | Total |
|---|---|---|---|---|---|---|
| Race — Asian | 6 | 12 | 6 | 5 | 2 | 31 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2017 to primary completion in Dec 2019, 33 months.
Results were first posted in Dec 2020, 1 year after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Hepatitis B, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's 33 months is close to that.
Counting every sponsor, half of 50 studies reached it within 30 months; a quarter within 19 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bepirovirsen